Since the index case of the series of Massoth et al. was a recurrent B3 thymoma biopsied after chemotherapy, and the treatment status of the other cases was not reported, it is currently unclear, whether the KMT2A-MAML2 translocation is an early or late molecular event. This evidence concerns the gene MAML2 and thymoma.